Project Grant HT94252510435
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$518K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Cold Spring Harbor, NY 11724, USA
Similar Awards
The federal Project Grant award, valued at $728,450.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by the Cold Spring Harbor Laboratory (CSHL) on the communication between cancer-associated fibroblasts and neurons, and how this interaction promotes the progression of pancreatic cancer. The award, which runs from July 1, 2025 to June 30, 2028, will enable CSHL to carry out advanced biomedical...
The U.S. Department of Defense's Defense Health Agency awarded a $384,000 Project Grant to the Cold Spring Harbor Laboratory (CSHL) to study the impact of recurrent acute pancreatitis on macrophage heterogeneity and function. This grant, awarded under the Military Medical Research and Development program (CFDA 12.420), will fund research aimed at improving the health and care of military service members, veterans, and their families. The grant has a performance period from February 1, 2024 to...
The Department of Defense's Defense Health Agency has awarded a $1,344,002 Project Grant to Cold Spring Harbor Laboratory (CSHL) under the Military Medical Research and Development program (CFDA 12.420). This four-year grant, running from August 1, 2024 to July 31, 2028, will fund research to enhance immunity in colorectal cancer liver metastases. CSHL, a renowned non-profit research institution, will leverage its expertise in cancer biology, genomics, and molecular biology to advance this...
The U.S. Department of the Army Medical Command awarded a $1,440,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program to Cold Spring Harbor Laboratory (CSHL) to conduct research on "Targeting Hypothalamic Neurons to Abrogate Stress-Induced Breast Cancer Growth." The grant, which runs from March 1, 2025 to February 29, 2028, will support advanced biomedical research initiatives focused on transforming healthcare for military service...
The Defense Health Agency awarded a $5.18 million project grant to the Sloan-Kettering Institute For Cancer Research to support research exploiting epigenetic vulnerabilities in breast cancers with chromosomal instability. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research and investigate medical solutions for battlefield wounds. Over a four-year period from May...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Defense Health Agency awarded a $524,664 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) through the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, which runs from December 1, 2024 to November 30, 2026, will fund research into the "Mechanisms of Irisin-Induced Cognitive Benefit in PD." DFCI, a prestigious non-profit cancer research center in Boston, will leverage its expertise in areas like oncology, immunology, and...
The Department of the Army Medical Command awarded $1,394,002 to Cold Spring Harbor Laboratory under the Military Medical Research and Development program (CFDA 12.420) on August 15, 2022 for a project grant with a completion date of August 14, 2025. Under this award, Cold Spring Harbor Laboratory and sub-awardees Weill Medical College of Cornell University will explore the relationship between sites of metastatic prostate cancer and the peripheral nerve system. Researchers will analyze human...
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
The Department of Defense's Defense Health Agency awarded a $2,212,500 Project Grant to the Sloan-Kettering Institute for Cancer Research (MSKCC) under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2023, supports a 4-year research project to define the genetic determinants of head and neck cancer progression and immune evasion through computational and functional investigation. The research aims to advance scientific understanding and...